178 related articles for article (PubMed ID: 32601377)
1. A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies.
Armand P; Lesokhin A; Borrello I; Timmerman J; Gutierrez M; Zhu L; Popa McKiver M; Ansell SM
Leukemia; 2021 Mar; 35(3):777-786. PubMed ID: 32601377
[TBL] [Abstract][Full Text] [Related]
2. Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma.
Glutsch V; Kneitz H; Gesierich A; Goebeler M; Haferkamp S; Becker JC; Ugurel S; Schilling B
Cancer Immunol Immunother; 2021 Jul; 70(7):2087-2093. PubMed ID: 33439294
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis.
Rangwala HS; Fatima H; Ali M; Sunder S; Devi S; Rangwala BS; Abbas SR
J Egypt Natl Canc Inst; 2024 May; 36(1):14. PubMed ID: 38705953
[TBL] [Abstract][Full Text] [Related]
4. Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial.
Andresen NK; Røssevold AH; Quaghebeur C; Gilje B; Boge B; Gombos A; Falk RS; Mathiesen RR; Julsrud L; Garred Ø; Russnes HG; Lereim RR; Chauhan SK; Lingjærde OC; Dunn C; Naume B; Kyte JA
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38242720
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis.
Mangla A; Lee C; Mirsky MM; Wang M; Rothermel LD; Hoehn R; Bordeaux JS; Carrol BT; Theuner J; Li S; Fu P; Kirkwood JM
JAMA Oncol; 2024 May; 10(5):612-620. PubMed ID: 38546551
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors.
Winter J; Lenders MM; Gassenmaier M; Forschner A; Leiter U; Weide B; Purde MT; Flatz L; Cozzio A; Röcken M; Garbe C; Eigentler TK; Wagner NB
Cancer Immunol Immunother; 2021 Apr; 70(4):1089-1099. PubMed ID: 33113003
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
Cascone T; Leung CH; Weissferdt A; Pataer A; Carter BW; Godoy MCB; Feldman H; William WN; Xi Y; Basu S; Sun JJ; Yadav SS; Rojas Alvarez FR; Lee Y; Mishra AK; Chen L; Pradhan M; Guo H; Sinjab A; Zhou N; Negrao MV; Le X; Gay CM; Tsao AS; Byers LA; Altan M; Glisson BS; Fossella FV; Elamin YY; Blumenschein G; Zhang J; Skoulidis F; Wu J; Mehran RJ; Rice DC; Walsh GL; Hofstetter WL; Rajaram R; Antonoff MB; Fujimoto J; Solis LM; Parra ER; Haymaker C; Wistuba II; Swisher SG; Vaporciyan AA; Lin HY; Wang J; Gibbons DL; Jack Lee J; Ajami NJ; Wargo JA; Allison JP; Sharma P; Kadara H; Heymach JV; Sepesi B
Nat Med; 2023 Mar; 29(3):593-604. PubMed ID: 36928818
[TBL] [Abstract][Full Text] [Related]
8. Adverse events of nivolumab plus ipilimumab versus nivolumab plus cabozantinib: a real-world pharmacovigilance study.
Oka Y; Matsumoto J; Takeda T; Iwata N; Niimura T; Ozaki AF; Bekku K; Hamano H; Araki M; Ishizawa K; Zamami Y; Ariyoshi N
Int J Clin Pharm; 2024 Jun; 46(3):745-750. PubMed ID: 38632203
[TBL] [Abstract][Full Text] [Related]
9. Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer.
Betts KA; Gao S; Ray S; Schoenfeld AJ
Future Oncol; 2024 Apr; 20(13):851-862. PubMed ID: 38240151
[TBL] [Abstract][Full Text] [Related]
10. Adverse Events of Cabozantinib Plus Nivolumab Versus Ipilimumab Plus Nivolumab.
Blas L; Shiota M; Tsukahara S; Nagakawa S; Matsumoto T; Eto M
Clin Genitourin Cancer; 2024 Feb; 22(1):e122-e127.e1. PubMed ID: 37813699
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.
Schenk KM; Deutsch JS; Chandra S; Davar D; Eroglu Z; Khushalani NI; Luke JJ; Ott PA; Sosman JA; Aggarwal V; Schollenberger MD; Sharfman WH; Bibee KP; Scott JF; Loss MJ; Wang H; Qi H; Sharon E; Streicher H; Chen HX; Woodward RN; Bagnasco SM; Taube JM; Topalian SL; Brennan DC; Lipson EJ
J Clin Oncol; 2024 Mar; 42(9):1011-1020. PubMed ID: 38252910
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade.
Mei M; Chen L; Godfrey J; Song J; Egelston C; Puverel S; Budde LE; Armenian S; Nikolaenko L; Nwangwu M; Guo W; Gao L; Lee P; Chen R; Daniels S; Kennedy N; Peters L; Zain J; Rosen S; Forman S; Popplewell L; Kwak L; Herrera AF
Blood; 2023 Oct; 142(16):1359-1370. PubMed ID: 37339586
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial.
Vos JL; Burman B; Jain S; Fitzgerald CWR; Sherman EJ; Dunn LA; Fetten JV; Michel LS; Kriplani A; Ng KK; Eng J; Tchekmedyian V; Haque S; Katabi N; Kuo F; Han CY; Nadeem Z; Yang W; Makarov V; Srivastava RM; Ostrovnaya I; Prasad M; Zuur CL; Riaz N; Pfister DG; Klebanoff CA; Chan TA; Ho AL; Morris LGT
Nat Med; 2023 Dec; 29(12):3077-3089. PubMed ID: 37620627
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study.
Haverkos B; Alpdogan O; Baiocchi R; Brammer JE; Feldman TA; Capra M; Brem EA; Nair S; Scheinberg P; Pereira J; Shune L; Joffe E; Young P; Spruill S; Katkov A; McRae R; Royston I; Faller DV; Rojkjaer L; Porcu P
Blood Adv; 2023 Oct; 7(20):6339-6350. PubMed ID: 37530631
[TBL] [Abstract][Full Text] [Related]
15. Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer.
Chen M; Nie J; Liu Y; Li X; Zhang Y; Brock MV; Feng K; Wu Z; Li X; Shi L; Li S; Guo M; Mei Q; Han W
Int J Cancer; 2018 Sep; 143(6):1530-1540. PubMed ID: 29663379
[TBL] [Abstract][Full Text] [Related]
16. Early on-treatment assessment of T-cells, cytokines and tumor DNA with adaptively-dosed nivolumab + ipilimumab: final results from the phase 2 ADAPT-IT study.
Smithy JW; Kalvin HL; Ehrich FD; Shah R; Adamow M; Raber V; Maher CA; Kleman J; McIntyre DAG; Shoushtari AN; Betof Warner A; Callahan MK; Momtaz P; Eton O; Nair S; Wolchok JD; Chapman PB; Berger MF; Panageas KS; Postow MA
Clin Cancer Res; 2024 May; ():. PubMed ID: 38767650
[TBL] [Abstract][Full Text] [Related]
17. Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report.
Takada R; Fujiwara M; Maki M; Nomura N; Kono S; Fujita A; Masumoto H; Takahashi Y; Hasegawa Y; Tamura K
J Pharm Health Care Sci; 2024 May; 10(1):26. PubMed ID: 38822426
[TBL] [Abstract][Full Text] [Related]
18. The lymphocyte-to-monocyte ratio as a significant inflammatory marker associated with survival of patients with metastatic renal cell carcinoma treated using nivolumab plus ipilimumab therapy.
Numakura K; Sekine Y; Osawa T; Naito S; Tokairin O; Muto Y; Sobu R; Kobayashi M; Sasagawa H; Yamamoto R; Nara T; Saito M; Narita S; Akashi H; Tsuchiya N; Shinohara N; Habuchi T
Int J Clin Oncol; 2024 May; ():. PubMed ID: 38797782
[TBL] [Abstract][Full Text] [Related]
19. Post-marketing surveillance of the safety and effectiveness of nivolumab for classic Hodgkin lymphoma in Japan.
Kawasaki A; Hatake K; Matsumura I; Izutsu K; Hoshino T; Akamatsu A; Kakuuchi A; Tobinai K
Int J Hematol; 2024 Jun; 119(6):667-676. PubMed ID: 38521840
[TBL] [Abstract][Full Text] [Related]
20. Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States.
Lurain K; Zarif TE; Ramaswami R; Nassar AH; Adib E; Abdel-Wahab N; Chintapally N; Drolen CE; Feldman T; Haykal T; Nebhan CA; Kambhampati S; Li M; Mittra A; Lorentsen M; Kim C; Drakaki A; Morse M; Johnson DB; Mangla A; Dittus C; Ravi P; Baiocchi RA; Chiao EY; Rubinstein PG; Yellapragada SV; LaCasce AS; Sonpavde GP; Naqash AR; Herrera AF
Clin Lymphoma Myeloma Leuk; 2024 Apr; ():. PubMed ID: 38714474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
